F S&P 500
5,211.00 +4.50 (+0.09%) F Dow Jones
39,057.00 +60.00 (+0.15%) F Nasdaq
18,188.25 -7.25 (-0.04%) E-mini Russell 2000 Index Futur
2,076.00 +4.90 (+0.24%) Petróleo
78.62 +0.14 (+0.18%) Oro
2,324.90 -6.30 (-0.27%)
Tenaya Therapeutics, Inc. (TNYA)
Fuera de horario:
Tenaya Therapeutics, Inc.
171 Oyster Point Boulevard
Suite 500
South San Francisco, CA 94080
United States
650 825 6990
https://www.tenayatherapeutics.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 140
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Faraz Ali M.B.A. | CEO & Director | 890.06k | N/D | 1973 |
| Dr. Deepak Srivastava M.D. | Scientific Founder, Chairman of Scientific Advisory Board & Director | 120.5k | N/D | 1967 |
| Ms. Leone D. Patterson M.B.A. | Chief Financial & Business Officer | 619.38k | N/D | 1962 |
| Dr. Whittemore G. Tingley M.D., PH.D. | Chief Medical Officer | 645.79k | N/D | 1968 |
| Dr. Eric N. Olson Ph.D. | Scientific Founder & Member of Scientific Advisory Board | N/D | N/D | N/D |
| Dr. Bruce R. Conklin | Scientific Founder | N/D | N/D | N/D |
| Dr. Saptarsi Haldar M.D. | Scientific Founder | N/D | N/D | N/D |
| Dr. Sheng Ding Ph.D. | Scientific Founder | N/D | N/D | N/D |
| Dr. Benoit G. Bruneau Ph.D. | Scientific Founder | N/D | N/D | N/D |
| Dr. Kee-Hong Kim Ph.D. | Chief Technology Officer | N/D | N/D | 1966 |
Descripción
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Tenaya Therapeutics, Inc. a partir del 1 de mayo de 2024 es 7. Las puntuaciones principales son Auditoría: 6; Junta: 7; Derechos del accionista: 8; Compensación: 8.
